Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer: A Nonrandomized Controlled Trial

Jian-Xian Lin, Yan-Chang Xu, Wei Lin, Fang-Qin Xue, Jian-Xin Ye, Wei-Dong Zang, Li-Sheng Cai, Jun You, Jian-Hua Xu, Jian-Chun Cai, Yi-Hui Tang, Jian-Wei Xie, Ping Li, Chao-Hui Zheng, Chang-Ming Huang, Jian-Xian Lin, Yan-Chang Xu, Wei Lin, Fang-Qin Xue, Jian-Xin Ye, Wei-Dong Zang, Li-Sheng Cai, Jun You, Jian-Hua Xu, Jian-Chun Cai, Yi-Hui Tang, Jian-Wei Xie, Ping Li, Chao-Hui Zheng, Chang-Ming Huang

Abstract

Importance: Apatinib is a novel treatment option for chemotherapy-refractory advanced gastric cancer (GC), but it has not been evaluated in patients with locally advanced GC.

Objective: To investigate the effectiveness and safety of apatinib combined with S-1 plus oxaliplatin (SOX) as a neoadjuvant treatment for locally advanced GC.

Design, setting, and participants: This multicenter, prospective, single-group, open-label, phase 2 nonrandomized controlled trial was conducted in 10 centers in southern China. Patients with M0 and either clinical T2 to T4 or N+ disease were enrolled between July 1, 2017, and June 30, 2019. Statistical analysis was performed from December 1, 2019, to January 31, 2020.

Interventions: Eligible patients received apatinib (500 mg orally once daily on days 1 to 21 and discontinued in the last cycle) plus SOX (S-1: 40-60 mg orally twice daily on days 1 to 14; oxaliplatin: 130 mg/m2 intravenously on day 1) every 3 weeks for 2 to 5 cycles. A D2 gastrectomy was performed 2 to 4 weeks after the last cycle.

Main outcomes and measures: The primary end point was R0 resection rate. Secondary end points were the response rate, toxic effects, and surgical outcome.

Results: A total of 48 patients (mean [SD] age, 63.2 [8.2] years; 37 men [77.1%]) were enrolled in this study. Forty patients underwent surgery (38 had gastrectomy, and 2 had exploratory laparotomy), with an R0 resection rate of 75.0% (95% CI, 60.4%-86.4%). The radiologic response rate was 75.0%, and T downstaging was observed in 16 of 44 patients (36.4%). The pathological response rate was 54.2% (95% CI, 39.2%-68.6%); moreover, this rate was significantly higher in patients who achieved a radiologic response compared with those who did not (12 [80.0%] vs 1 [20.0%]; P = .03) and in those who had an Eastern Cooperative Oncology Group Performance Status score of 0 (20 [76.9%] vs 10 [45.5%]; P = .03) or had tumors located in the upper one-third of the stomach (16 [61.5%] vs 7 [31.8%]; P = .04). Patients who achieved a pathological response (vs those who did not) had significantly less blood loss (median [range]: 60 [10-200] mL vs 80 [20-300] mL; P = .04) and significantly more lymph nodes harvested (median [range]: 40 [24-67] vs 32 [19-51]; P = .04) during surgery. Postoperative complications were observed in 7 of 38 patients (18.4%). Grade 3 toxic effects occurred in 16 of 48 patients (33.3%), and no grade 4 toxic effects or preoperative deaths were observed.

Conclusions and relevance: This nonrandomized controlled trial found that apatinib combined with SOX was effective and had an acceptable safety profile as a neoadjuvant treatment for locally advanced GC. A large-scale randomized clinical trial may be needed to confirm the findings.

Trial registration: ClinicalTrials.gov Identifier: NCT03192735.

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure.. COHORT Diagram of Study Population
Figure.. COHORT Diagram of Study Population

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492
    1. Pyo JH, Lee H, Min BH, et al. . Long-term outcome of endoscopic resection vs. surgery for early gastric cancer: a non-inferiority-matched cohort study. Am J Gastroenterol. 2016;111(2):240-249. doi:10.1038/ajg.2015.427
    1. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439-449. doi:10.1016/S1470-2045(10)70070-X
    1. Cunningham D, Allum WH, Stenning SP, et al. ; MAGIC Trial Participants . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20. doi:10.1056/NEJMoa055531
    1. NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. Version 2.2015. National Comprehensive Cancer Network; 2015.
    1. Okines AFC, Norman AR, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. 2009;20(9):1529-1534. doi:10.1093/annonc/mdp047
    1. Yamada Y, Higuchi K, Nishikawa K, et al. . Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 2015;26(1):141-148. doi:10.1093/annonc/mdu472
    1. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903-2909. doi:10.1200/JCO.2005.05.0245
    1. Cunningham D, Okines AF, Ashley S. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2010;362(9):858-859. doi:10.1056/NEJMc0911925
    1. Bang YJ, Van Cutsem E, Feyereislova A, et al. ; ToGA Trial Investigators . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697. doi:10.1016/S0140-6736(10)61121-X
    1. Ohtsu A, Ajani JA, Bai YX, et al. . Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013;31(31):3935-3943. doi:10.1200/JCO.2012.48.3552
    1. Okines AF, Ashley SE, Cunningham D, et al. . Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol. 2010;28(25):3945-3950. doi:10.1200/JCO.2010.29.2847
    1. Satoh T, Xu RH, Chung HC, et al. . Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study. J Clin Oncol. 2014;32(19):2039-2049. doi:10.1200/JCO.2013.53.6136
    1. de Mello RA, Marques AM, Araújo A. HER2 therapies and gastric cancer: a step forward. World J Gastroenterol. 2013;19(37):6165-6169. doi:10.3748/wjg.v19.i37.6165
    1. Janjigian YY, Werner D, Pauligk C, et al. . Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012;23(10):2656-2662. doi:10.1093/annonc/mds104
    1. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011-1027. doi:10.1200/JCO.2005.06.081
    1. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 2007;19(10):2003-2012. doi:10.1016/j.cellsig.2007.05.013
    1. Tian S, Quan H, Xie C, et al. . YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102(7):1374-1380. doi:10.1111/j.1349-7006.2011.01939.x
    1. Li J, Qin S, Xu J, et al. . Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448-1454. doi:10.1200/JCO.2015.63.5995
    1. Li W, Qin J, Sun YH, Liu TS. Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J Gastroenterol. 2010;16(44):5621-5628. doi:10.3748/wjg.v16.i44.5621
    1. Ott K, Lordick F, Herrmann K, Krause BJ, Schuhmacher C, Siewert JR. The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer. 2008;11(1):1-9. doi:10.1007/s10120-007-0448-1
    1. World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053
    1. Japanese Gastric Cancer Association . Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1-19. doi:10.1007/s10120-016-0622-4
    1. Amin MB, Edge S, Greene F, et al. , eds. AJCC Cancer Staging Manual. 8th ed. Springer; 2017. doi:10.1007/978-3-319-40618-3
    1. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205-213. doi:10.1097/
    1. Eisenhauer EA, Therasse P, Bogaerts J, et al. . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. doi:10.1016/j.ejca.2008.10.026
    1. Japanese Gastric Cancer Association . Japanese Classification of Gastric Carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101-112. doi:10.1007/s10120-011-0041-5
    1. Becker K, Mueller JD, Schulmacher C, et al. . Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98(7):1521-1530. doi:10.1002/cncr.11660
    1. Roviello G, Petrioli R, Marano L, et al. . Angiogenesis inhibitors in gastric and gastroesophageal junction cancer. Gastric Cancer. 2016;19(1):31-41. doi:10.1007/s10120-015-0537-5
    1. Kang YK, Kang WK, Di Bartolomeo M, et al. . Randomized phase 3 ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer. September 29, 2019. Accessed November 7, 2019.
    1. Zheng Y, Yang X, Yan C, et al. . Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: a single-arm, open-label, phase II trial. Eur J Cancer. 2020;130:12-19. doi:10.1016/j.ejca.2020.02.013
    1. Martin RC II, Jaques DP, Brennan MF, Karpeh M. Achieving RO resection for locally advanced gastric cancer: is it worth the risk of multiorgan resection? J Am Coll Surg. 2002;194(5):568-577. doi:10.1016/S1072-7515(02)01116-X
    1. Wang SY, Yeh CN, Lee HL, et al. . Clinical impact of positive surgical margin status on gastric cancer patients undergoing gastrectomy. Ann Surg Oncol. 2009;16(10):2738-2743. doi:10.1245/s10434-009-0616-0
    1. Nagata T, Ichikawa D, Komatsu S, et al. . Prognostic impact of microscopic positive margin in gastric cancer patients. J Surg Oncol. 2011;104(6):592-597. doi:10.1002/jso.22022
    1. Ychou M, Boige V, Pignon JP, et al. . Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715-1721. doi:10.1200/JCO.2010.33.0597
    1. Al-Batran SE, Hofheinz RD, Pauligk C, et al. . Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17(12):1697-1708. doi:10.1016/S1470-2045(16)30531-9
    1. Becker K, Langer R, Reim D, et al. . Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg. 2011;253(5):934-939. doi:10.1097/SLA.0b013e318216f449
    1. Donohoe CL, O’Farrell NJ, Grant T, et al. . Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: assessment of existing measures and proposal of a novel 3-point standard. Ann Surg. 2013;258(5):784-792. doi:10.1097/SLA.0b013e3182a66588
    1. Schuhmacher C, Gretschel S, Lordick F, et al. . Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28(35):5210-5218. doi:10.1200/JCO.2009.26.6114
    1. Shrikhande SV, Barreto SG, Talole SD, et al. . D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy. World J Surg Oncol. 2013;11:31. doi:10.1186/1477-7819-11-31
    1. Ohtsu A, Shah MA, Van Cutsem E, et al. . Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968-3976. doi:10.1200/JCO.2011.36.2236
    1. Fuchs CS, Tomasek J, Yong CJ, et al. ; REGARD Trial Investigators . Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31-39. doi:10.1016/S0140-6736(13)61719-5
    1. Zhao Q, Li Y, Huang J, et al. . Short-term curative effect of S-1 plus oxaliplatin as perioperative chemotherapy for locally advanced gastric cancer: a prospective comparison study. Pharmazie. 2017;72(4):236-240. doi:10.1691/ph.2017.6865
    1. Aoyama T, Nishikawa K, Fujitani K, et al. . Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer. Ann Oncol. 2017;28(8):1876-1881. doi:10.1093/annonc/mdx236

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever